3 Specialty Generics and Branded Formulations Maker, Domestic Brands Specialist and Oncology Focused Drug Maker Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma

Specialty and complex generics pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma cover a specialty generics and branded formulations maker, a domestic brands specialist and an oncology focused drug maker.

This list covers three specialty and complex generics pharma stocks with complete current figures: Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Specialty and Complex Generics Pharma Stocks?

Specialty and complex generics pharma stocks are listed pharmaceutical companies that make specialty generics, domestic branded medicines and complex cancer and other hard-to-make formulations for India and export markets. Their earnings depend on product launches, regulatory approvals, pricing and currency.

Specialty and Complex Generics Pharma Stocks at a Glance

On valuation, Alembic Pharmaceuticals and Natco Pharma trade at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing specialty and complex generics pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Specialty and Complex Generics Pharma Stocks Have a Strong Roadmap in India?

Specialty and complex generics pharma stocks have a strong roadmap in India because complex product launches, strong domestic brands and rising demand for cancer and chronic care medicines keep widening the market for Indian pharmaceutical companies.

• Complex products. Hard-to-make drugs earn better margins.
• Domestic brands. Chronic and acute brands build loyalty.
• Oncology focus. Cancer treatment demand keeps rising.

Why Alembic Pharmaceuticals Features Among These Specialty and Complex Generics Pharma Stocks

Among the specialty and complex generics pharma stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why JB Chemicals and Pharmaceuticals Features Among These Specialty and Complex Generics Pharma Stocks

Among the domestic brands and oncology generics shares on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Natco Pharma Features Among These Specialty and Complex Generics Pharma Stocks

Among the three companies on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.

The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.

Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.

Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.

Alembic Pharmaceuticals vs JB Chemicals and Pharmaceuticals vs Natco Pharma on Key Financials

The table below sets the three specialty and complex generics pharma stocks side by side on revenue, profit and margin, using reported figures.

JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with specialty and complex generics pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Specialty and Complex Generics Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these specialty and complex generics pharma stocks, the main points are: Long-term domestic brands and oncology generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter specialty and complex generics pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Specialty and Complex Generics Pharma Stocks

Specialty and complex generics pharma stocks work best when investors track growth, valuation and return on equity side by side. Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma each have a clear plan to expand. Based on the 27 October 2026 close, Alembic Pharmaceuticals trades at Rs 766.9, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Natco Pharma at Rs 794.55.

Download the Univest iOS App or Univest Android App to track specialty and complex generics pharma stocks, set price alerts and get research-backed stock ideas.

What are specialty and complex generics pharma stocks?

Ans. Specialty and complex generics pharma stocks are listed pharmaceutical companies that make specialty generics, domestic branded medicines and complex cancer and other hard-to-make formulations for India and export markets. Their earnings depend on product launches, regulatory approvals, pricing and currency. This list looks at three of them, Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which specialty and complex generics pharma stocks are covered in this list?

Ans. This list covers Alembic Pharmaceuticals, JB Chemicals and Pharmaceuticals and Natco Pharma. Based on the 27 October 2026 close, Alembic Pharmaceuticals traded at Rs 766.9, JB Chemicals and Pharmaceuticals at Rs 2,408.9 and Natco Pharma at Rs 794.55. Their return on equity ranges from 11.9% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 21.0%.

Why do specialty and complex generics pharma stocks have a strong future roadmap in India?

Ans. Specialty and complex generics pharma stocks have a strong roadmap in India because complex product launches, strong domestic brands and rising demand for cancer and chronic care medicines keep widening the market for Indian pharmaceutical companies. The main drivers are as follows. Complex products. Hard-to-make drugs earn better margins. Domestic brands. Chronic and acute brands build loyalty. Oncology focus. Cancer treatment demand keeps rising. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Natco Pharma performed financially?

Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.

What risks should investors check before buying specialty and complex generics pharma stocks?

Ans. Investors should check a few risks before buying specialty and complex generics pharma stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of specialty and complex generics pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.